Lee S. Schwartzberg, MD, FACP

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.